Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A… (NCT07447128) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Project
United States50 participantsStarted 2026-07-27
Plain-language summary
This study will test whether patients who already have a permanent dialysis access (an arteriovenous fistula or graft) can safely use that access for continuous dialysis (CRRT) while they are critically ill in the intensive care unit, instead of requiring a temporary central venous catheter. About 50 patients will participate. Researchers will monitor how well the access works, whether any complications occur, and whether there are differences between fistulas and grafts. The goal is to determine whether using a patient's existing dialysis access is a safe and practical option that could reduce the need for temporary catheters and their associated risks, such as infection and bleeding.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years.
. ESKD patients on chronic hemodialysis for \>1 year in duration who are admitted to the ICU and in need of CRRT.
. Anticipated CRRT duration ≥24 hours, based on clinical assessment of the renal trajectory.
. Patient with functioning arteriovenous access, either arteriovenous fistula or arteriovenous graft.
. Expected mechanical ventilation for a minimum of 12 hours, based on clinical assessment of the underlying diagnosis.
. Expected Richmond Agitation Sedation Scale (RASS) goal of 0 or less for a minimum of 12 hours, based on clinical assessment of the underlying diagnosis.
. Patients able to tolerate placement of an arm board at the vascular access site.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is looking at how well arteriovenous access holds up during continuous renal replacement therapy — can you explain how AV access is different from the standard venous catheters typically used for CRRT, and whether that difference matters for my situation?
2Since this study isn't recruiting yet, how long do you think it might be before it opens, and is there a reason to wait for it rather than moving forward with a treatment plan now?
3The trial is observational and measuring 'access survival' — does that mean patients aren't being assigned to a new treatment, and if so, what would my actual care look like if I were eventually enrolled?
4Given that this is listed as phase 'not applicable,' what does that tell us about the level of evidence behind AV access for CRRT, and are there already published studies you'd want me to review before considering this?
5For someone with end-stage kidney disease who may need ongoing renal replacement therapy, would participating in a study like this conflict with or delay any other treatment options — like preparing for long-term dialysis or a kidney transplant evaluation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Technical Feasibility of using Arteriovenous Access for CRRT delivery
Timeframe: From initiation of CRRT until discontinuation of CRRT, ICU discharge or 7 days post-CRRT (whichever occurs first), and 30 days post-CRRT via chart review.
2
Access-related serious complications
Timeframe: From initiation of CRRT until discontinuation of CRRT, ICU discharge or 7 days post-CRRT (whichever occurs first), and 30 days post-CRRT via chart review.
. Baseline AVA blood flow of at least 600 mL/min for AVG and 500 mL/min for AVF during ultrasonography evaluation upon enrollment.
Exclusion criteria
. Age less than 18 years old.
. Patients who receive dialysis via hemodialysis catheter or existing central catheter suitable for hemodialysis.
. ESKD patients who, at the time of enrollment, have a sacral pressure ulcer or other clinically significant skin integrity impairment requiring frequent repositioning, extensive patient rotation, or advanced wound care management.
. Patients with elevated INR above 5 at the time of study enrollment.
. Patients with acute liver failure, defined as AST \>1000 U/L and/or ALT \>1000 U/L at the time of study enrollment.
. Patients with a platelet count of less than 50,000 (10⁹ plt/L) at the time of study enrollment.
. Patients with evidence of disseminated intravascular coagulation at the time of study enrollment.
. Known pregnancy at the time of study enrollment.